Novo Nordisk's Oral Semaglutide Prescriptions Surpass 26,000

Deep News01-30

According to data shared by an analyst on Friday, prescriptions for Novo Nordisk's oral semaglutide tablets exceeded 26,000 in the United States during the drug's second full week on the market. Investors are closely monitoring prescription figures to gauge whether the Danish pharmaceutical giant can maintain its first-mover advantage against competitor Eli Lilly LLY.N in the fiercely competitive weight-loss market. Analysts from Barclays wrote in a report that weekly prescriptions for the semaglutide tablets reached 26,109 for the period ending January 23, indicating a very robust launch momentum for the oral medication. The drug recorded 3,071 U.S. prescriptions in its first four days following the January 5 launch, and reached over 18,000 prescriptions in the week ending January 16.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1143762998?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-30 20:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1143762998","market":"fut","top_or_hot":-1,"title":"Novo Nordisk's Oral Semaglutide Prescriptions Surpass 26,000","media":"Deep News","content":"<p>According to data shared by an analyst on Friday, prescriptions for Novo Nordisk's oral semaglutide tablets exceeded 26,000 in the United States during the drug's second full week on the market.\nInvestors are closely monitoring prescription figures to gauge whether the Danish pharmaceutical giant can maintain its first-mover advantage against competitor Eli Lilly LLY.N in the fiercely competitive weight-loss market.\nAnalysts from Barclays wrote in a report that weekly prescriptions for the semaglutide tablets reached 26,109 for the period ending January 23, indicating a very robust launch momentum for the oral medication.\nThe drug recorded 3,071 U.S. prescriptions in its first four days following the January 5 launch, and reached over 18,000 prescriptions in the week ending January 16.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk's Oral Semaglutide Prescriptions Surpass 26,000</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk's Oral Semaglutide Prescriptions Surpass 26,000\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-01-30 20:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>According to data shared by an analyst on Friday, prescriptions for Novo Nordisk's oral semaglutide tablets exceeded 26,000 in the United States during the drug's second full week on the market.\nInvestors are closely monitoring prescription figures to gauge whether the Danish pharmaceutical giant can maintain its first-mover advantage against competitor Eli Lilly LLY.N in the fiercely competitive weight-loss market.\nAnalysts from Barclays wrote in a report that weekly prescriptions for the semaglutide tablets reached 26,109 for the period ending January 23, indicating a very robust launch momentum for the oral medication.\nThe drug recorded 3,071 U.S. prescriptions in its first four days following the January 5 launch, and reached over 18,000 prescriptions in the week ending January 16.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4599","symbol_name":"减肥药","start_time":0,"source_url":"","article_id":"1143762998","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1143762998","pubTimestamp":1769776901,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"According to data shared by an analyst on Friday, prescriptions for Novo Nordisk's oral semaglutide tablets exceeded 26,000 in the United States during the drug's second full week on the market....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4599":"减肥药","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4007":"制药","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4588":"碎股","BK4585":"ETF&股票定投概念","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","NVO":"诺和诺德","BK4532":"文艺复兴科技持仓"},"translate_title":"诺和诺德口服索马鲁肽处方超2.6万张","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"According to data shared by an analyst on Friday, prescriptions for Novo Nordisk's oral semaglutide tablets exceeded 26,000 in the United States during the drug's second full week on the market.\nInvestors are closely monitoring prescription figures to gauge whether the Danish pharmaceutical giant can maintain its first-mover advantage against competitor Eli Lilly LLY.N in the fiercely competitive weight-loss market.\nAnalysts from Barclays wrote in a report that weekly prescriptions for the semaglutide tablets reached 26,109 for the period ending January 23, indicating a very robust launch momentum for the oral medication.\nThe drug recorded 3,071 U.S. prescriptions in its first four days following the January 5 launch, and reached over 18,000 prescriptions in the week ending January 16.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1143762998","isCrawlerRequest":true}